References
- Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccin Immunother. 2014;10(6):1466–1477.
- Lyras D, O’Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009;458(7242):1176–1179.
- Johnson S, Sambol SP, Brazier JS, et al. International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants. J Clin Microbiol. 2003;41(4):1543–1547.
- Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010;28(4):965–969.
- Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. N Engl J Med. 2017;376(4):305–317.
- Hong HA, Hitri K, Hosseini S, et al. Mucosal antibodies to the C terminus of toxin a prevent colonization of clostridium difficile. Infect Immun. 2017;85(4). pii: e01060-16. doi:10.1128/IAI.01060-16.
- Larabee JL, Krumholz A, Hunt JJ, et al. Exposure of neutralizing epitopes in the carboxyl-terminal domain of TcdB is altered by a proximal hypervariable region. J Biol Chem. 2015;290(11):6975–6985.
- Eckert C, Emirian A, Le Monnier A, et al. Prevalence and pathogenicity of binary toxin-positive Clostridium difficile strains that do not produce toxins A and B. New Microbes New Infect. 2015;3:12–17.
- Secore S, Wang S, Doughtry J, et al. Development of a novel vaccine containing binary toxin for the prevention of clostridium difficile disease with enhanced efficacy against NAP1 strains. PloS One. 2017;12(1):e0170640.
- Devera TS, Lang GA, Lanis JM, et al. Memory B cells encode neutralizing antibody specific for toxin B from the clostridium difficile strains VPI 10463 and NAP1/BI/027 but with superior neutralization of VPI 10463 toxin B. Infect Immun. 2016;84(1):194–204.
- Bauer MP, Nibbering PH, Poxton IR, et al. Humoral immune response as predictor of recurrence in Clostridium difficile infection. Clin Microbiol Infect. 2014;20(12):1323–1328.
- Monteiro MA, Ma Z, Bertolo L, et al. Carbohydrate-based Clostridium difficile vaccines. Expert Rev Vaccines. 2013;12(4):421–431.
- Chu M, Mallozzi MJ, Roxas BP, et al. A clostridium difficile cell wall glycopolymer locus influences bacterial shape, polysaccharide production and virulence. PLoS Pathog. 2016;12(10):e1005946.
- Hutter J, Lepenies B. Carbohydrate-based vaccines: an overview. Methods Mol Biol. 2015;1331:1–10.
- Oleszycka E, Lavelle EC. Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol. 2014;28:1–5.
- Bezay N, Ayad A, Dubischar K, et al. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016;34(23):2585–2592.
- Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017;17(1):21–29.
- Nakamura S, Mikawa M, Nakashio S, et al. Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol. 1981;25(4):345–351.
- Monaghan TM, Robins A, Knox A, et al. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile -associated diarrhoea, inflammatory bowel disease and cystic fibrosis. PloS One. 2013;8(9):e74452.
- de Bruyn G, Saleh J, Workman D, et al. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: a randomized Phase 2 clinical trial. Vaccine. 2016;34(19):2170–2178.